What if your dentist could spot cavities long before they became a problem? Join us as we chat with Jordan Rubinson, CEO of CaviSense, about his interesting journey from pharma to medtech We start by discussing Jordan's early influences, from his father's career at Block Drug Company to his own academic adventures at Columbia and MIT's Sloan School. Despite an initial interest in accounting, Jordan's passion for pharma led him down a path less traveled, avoiding the conventional business routes of consulting and investment banking.

Next, we take a closer look at Jordan's dynamic career in the pharmaceutical industry. Learn how his family's frequent relocations led to professional opportunities across the globe. Jordan shares anecdotes from his time in big pharma, including his experiences within a management development program at Sanofi Pasteur and the challenges of managing diverse roles in different markets. His shift from big pharma to the innovative medtech startup scene in Israel provides a compelling narrative about the contrasts between structured environments and the fast-paced, resource-tight nature of startups.

Finally, we explore the evolving role of dentists as both medical professionals and entrepreneurs. Discover how new technologies are revolutionizing dental care, especially in pediatric dentistry. Jordan introduces us to CaviSense, a groundbreaking tool for early cavity detection, and discusses its journey from early development to FDA registration. We also touch on the exciting future of consumer-friendly dental monitoring tools that could transform how we manage oral health at home.

Don't miss this episode to hear about the future of interactive dental care and the potential for improved patient outcomes.

Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.

Travis Morgan, President and CFO of DecisionRx touts medication optimization as the way to improve outcomes and reduce costs. In this episode, Travis shares his journey from an entrepreneurial upbringing to making waves in the life sciences and healthcare technology sectors. Learn how his experiences in public accounting and as a precision medicine company co-founder have shaped his unique approach to tackling one of the healthcare industry's most costly issues: ineffective medications.

Hear how DecisionRx is leveraging pharmacogenomics and data science to improve patient outcomes and reduce healthcare expenses. Travis explains the impact of pharmacist-led interventions , and how the value-based care model, combined with genetic analysis, can guides clinical decision to prevent medication failures. Get insights into the commercial success of this approach, particularly within risk-bearing entities like ACOs and Medicare Advantage plans.

Learn about the power of innovative medication optimization, eliminating the usual friction associated with third-party reimbursement. Travis discusses the company's scale-up effort, with over 230,000 lives under contract through accountable care organizations and substantial financial backing from the Carlyle Group.

Finally, hear why Travis recommends "Endurance: The Biography of Ernest Shackleton," as an essential read for any aspiring leader.

Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.

Curious about the forces driving healthcare pricing and access? Join us for an enlightening conversation with Sarah Emond, President and CEO of the Institute for Clinical and Economic Review (ICER). Sarah's upbringing in a family passionate about policy and social justice laid the foundation for her impactful career in health policy. We explore her educational journey from Smith College to Brandeis University’s Heller School, and how her professional experiences in clinical research and biopharmaceutical consulting shaped her path to ICER.

Unravel the complex world of health technology assessment (HTA) in the US as Sarah breaks down the challenges and opportunities within a fragmented healthcare system. ICER's pivotal role in evaluating new medical technologies is discussed in depth, including its interactions with international agencies like the UK's NICE. Sarah sheds light on ICER's evolution from a small initiative within Mass General Hospital to a powerful voice in global HTA practices, emphasizing the importance of fair pricing, patient access, and sustainable innovation funding.

Equity in healthcare takes center stage as Sarah introduces ICER’s updated value assessment framework. Learn about new tools like the clinical trial diversity rating and the Health Improvement Distribution Index (HIDI) designed to promote representation of diverse populations in clinical trials. We also tackle the high costs and value-based pricing of innovative treatments, including gene and cell therapies, and the necessity of evolving payment systems to ensure continuous innovation. Tune in to gain a comprehensive understanding of the pressing challenges and future directions in healthcare pricing, equity, and access.

Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.